United Therapeutics Corporation

Good morning and welcome to the United Therapeutics Corporation third quarter 2024 earnings webcast. My name is Dave and I will be your conference operator today. All participants on the call portion of this webcast will be in listen-only mode. until the question and answer portion of this earnings call. If you would like to ask a question during the call, simply press star and then one on your telephone keypad. If you would like to withdraw your question, please press star and then two. Please note this call is being recorded. I would now like to turn the webcast over to Dewey Stedman, Head of Investor Relations at United Therapeutics.

Thank you, Dave, and good morning. It's my pleasure to welcome you to the United Therapeutics Corporation third quarter 2024 earnings webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events, and these statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties, and we assume no obligation to update these forward-looking statements. Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products, and these remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the products are available on our website. Accompanying me on today's call are Dr. Martine Rothblatt, our chairperson and chief executive officer, Michael Binkowitz, our President and Chief Operating Officer, James Edgmund, our Chief Financial Officer and Treasurer, Dr. Lee Peterson, our Executive Vice President of Product Development and Xenotransplantation, and Pat Poisson, our Executive Vice President of Technical Operations. Note that Pat Poisson and I will participate in a fireside chat session and one-on-one meetings at the UBS Global Healthcare Conference outside of Los Angeles on November 12th. Along with Harry Silvers from our Investor Relations team, I will be at the Oppenheimer Rare Disease Day in New York City on December 12th. And finally, Martine Roplot will present at the 43rd Annual JPMorgan Healthcare Conference in San Francisco in January. Our Scientific, Commercial, and Medical Affairs teams will present at the Phenomenal Hope 2024 on December 6th in Boston, and at the Pulmonary Vascular Research Institute Annual Congress in Rio de Janeiro in late January. Now I will turn the webcast over to Martine for an overview of our third quarter 2024 financial results and the business activities of United Therapeutics.

Martine?